Medicaid Access to Longer-Acting Injectable Products for HIV Treatment and Prevention

Medicaid is the largest source of insurance coverage for people living with HIV and a major source of coverage for pre-exposure prophylaxis (PrEP), a critical HIV-prevention tool. With the expansion of long-acting injectable products for HIV treatment and prevention on the horizon, it is important to be aware of the tools used by Medicaid programs to manage prescription drug benefits and policy issues that must be addressed to protect access.

Amida Care collaborated with the O’Neill Institute of National and Global Health Law and the Cicatelli Associates (CAI) TAP-in project to publish this “Quick Take” on the issue.

Read it here